Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bladder. Risk and prognostic factors--a pathologist's perspective.

V E Reuter1

  • 1Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. reuterv@mskcc.org

The Urologic Clinics of North America
|September 24, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ-cell tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Reply by Authors.

The Journal of urology·2020
Same author

Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference.

European radiology·2015
Same author

Reversal of the low-affinity neurotrophin receptor stromal-epithelial expression pattern between benign and malignant human prostate.

Urologic oncology·2011
Same author

Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.

British journal of cancer·2010
Same author

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma.

Neurology·2009

Bladder cancer morphology is crucial for predicting outcomes and treatment response. Further research is needed to standardize criteria and compare novel molecular tools with established morphologic and clinical markers.

Area of Science:

  • Uropathology
  • Oncology
  • Cancer Research

Background:

  • Morphological assessment is a key method for predicting bladder cancer prognosis, including recurrence, progression, and therapy response.
  • Standardization of criteria and terminology in bladder cancer morphology is currently lacking.
  • Emerging molecular tools offer potential prognostic insights but require validation.

Purpose of the Study:

  • To highlight the importance of morphology in bladder cancer prognostication.
  • To emphasize the need for refining and standardizing morphological criteria.
  • To advocate for prospective comparative studies of molecular and morphologic markers.

Main Methods:

  • Review of current literature on bladder cancer morphology and molecular markers.

Related Experiment Videos

  • Discussion on the necessity of multivariate analysis for comparing prognostic factors.
  • Emphasis on prospective study designs.

    • Main Results:

    • Morphology is an established prognostic tool in bladder cancer.
    • There is a clear need for improved standardization in morphological assessment.
    • Molecular markers require rigorous comparison with existing clinical and morphologic data.

    Conclusions:

    • Morphology remains a vital component in predicting bladder cancer outcomes.
    • Standardization of diagnostic criteria and terminology is essential for consistent prognostication.
    • Future research should prospectively validate novel molecular markers against established methods using multivariate analysis.